Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) (WRAIR)

• ClinicalTrials.gov Identifier: NCT03992872
• Recruitment Status: Completed
• First Posted: June 20, 2019
• Last Update Posted: July 3, 2023
• Sponsor: Bavarian Nordic
• Collaborators: Walter Reed Army Institute of Research (WRAIR); Emergent BioSolutions
• Information provided by (Responsible Party): Bavarian Nordic

Study Description

Brief Summary:

This is a Phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317) in prior recipients of other alphavirus vaccines versus alphavirus naïve controls.

Condition or disease	Intervention/treatment	Phase
Chikungunya	Biological: Chikungunya	Phase 2

Detailed Description:

It is currently unknown whether prior exposure to heterologous alphaviruses will enhance or interfere with immune responses to chikungunya virus (CHIKV) exposure or vaccination. The objective of this study is to evaluate the safety and immunogenicity of the chikungunya vaccine candidate PXVX0317 when administered to prior recipients of experimental alphavirus vaccines versus alphavirus naïve gender- and age-matched controls.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 60 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Open Label Safety and Immunogenicity
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus Naïve Controls.
• Actual Study Start Date: November 20, 2019
• Actual Primary Completion Date: January 19, 2021
• Actual Study Completion Date: January 19, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Prior Alpha; All study participants will receive the same Investigational Product according to the same schedule. Subjects are prior recipients of experimental alphavirus vaccines.	Biological: Chikungunya; Virus Like Particle
Active Comparator: Control: Naïve Alpha; All study participants will receive the same Investigational Product according to the same schedule. The alphavirus vaccine naïve subjects will serve as controls for determining the effect of pre-existing alphavirus immunity on vaccine safety and immunogenicity.	Biological: Chikungunya; Virus Like Particle

Outcome Measures

Primary Outcome Measures :

1. Neutralizing Antibody Response [ Time Frame: 182 days ]
   Evaluate the neutralizing antibody response to chikungunya virus induced by PXVX0317 when administered to prior alphavirus vaccine recipients versus gender- and age-matched controls

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Age 18 to 65 years old (inclusive)
• For women of childbearing potential, a negative pregnancy test at screening and on vaccination day, practicing highly effective contraception for at least 30 days prior to vaccination, and willing to use a highly effective method of contraception through study completion.
• Able and willing to provide informed consent for study participation prior to screening procedures.
• Free of obvious health problems as established by medical history and clinical examination at screening and enrollment.
• Available to participate for the duration of the study (approximately 8 months).
• For the cohort of prior alphavirus vaccine recipients, a documented history of prior alphavirus vaccination.

Exclusion Criteria:

• Acute disease or febrile illness at the time of screening or enrollment.
• Clinically significant cardiac, respiratory, rheumatologic or other medical or psychiatric condition that, in the opinion of the Investigator, places the subject at increased risk or affects their ability to understand and comply with study procedures.
• Abnormal screening lab test result that, in the opinion of the investigator, obscures interpretation of the safety data or suggests a clinically significant cardiac, respiratory, rheumatologic or other medical condition that places the subject at increased risk.
• Pregnant, lactating or planning to become pregnant during the study period.
• Laboratory evidence of infection with Hepatitis B, C or HIV.
• History of naturally (non-laboratory) acquired chikungunya or other alphavirus infection or travel to a WHO-designated chikungunya-endemic region within 30 days prior to Day 1.
• History of acute allergic reaction to any component of CHIKV-VLP vaccine or Alhydrogel®.
• Current (30 days prior to Day 1) or anticipated use of systemic immunomodulatory or immunosuppressive medications.
• History of splenectomy, immunosuppressive condition, autoimmune disease, or immunodeficient condition.
• Family history of congenital or hereditary immunodeficiency.
• Suspected or known current alcohol abuse that, in the opinion of the Investigator, would interfere with the subject's ability to understand and comply with study procedures.
• Current intravenous drug use.
• Prior receipt of an investigational chikungunya vaccine.
• Receipt or planned receipt of any licensed vaccine from 30 days prior to Day 1 through Day 29 study visit.
• Participation in another clinical trial during the study period in which an investigational product is administered.
• For the alphavirus naïve group, history of prior alphavirus vaccination is exclusionary.

Contacts and Locations

Locations

United States, Maryland

United States Army Medical Research Institute of Infectious Diseases

Fort Deterick, Maryland, United States, 21702

Walter Reed Army Institute of Research

Silver Spring, Maryland, United States, 20910

Sponsors and Collaborators

Bavarian Nordic

Walter Reed Army Institute of Research (WRAIR)

Emergent BioSolutions

Investigators

• Study Director: James McCarty, MD; Emergent BioSolutions

  Study Documents (Full-Text)

Documents provided by Bavarian Nordic:

Informed Consent Form  [PDF] October 10, 2019

More Information

• Responsible Party: Bavarian Nordic
• ClinicalTrials.gov Identifier: NCT03992872
• Other Study ID Numbers: EBSI-CV-317-002
• First Posted: June 20, 2019
• Last Update Posted: July 3, 2023
• Last Verified: June 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Chikungunya Fever; Alphavirus Infections; Arbovirus Infections; Vector Borne Diseases; Infections; Virus Diseases; Togaviridae Infections; RNA Virus Infections